11,12-Epoxyeicosatrienoic acid

From NuGOwiki

Jump to: navigation, search

The NuGOwiki Metabolite Database is a joint initiative of NuGO and HMDB

Taxonomy Navigation Box; search by

All Metabolites | Biochemical | Nutritional | Functional | Metabolic Pathways | Diseases | Phenotypes | Physiological Processes | Protein

11,12-Epoxyeicosatrienoic acid
2D structure for 11,12-Epoxyeicosatrienoic acid
Chemical Name (5E,8E)-10-[3-[(E)-oct-2-enyl]oxiran-2-yl]deca-5,8-dienoic acid
Chemical Formula C20H32O3
CAS Number 81276-02-0
Chemical Information HMDB04673
Biochemical Taxonomy

  • Fatty Acids

Functional Taxonomy Not Available
Nutritional Taxonomy Not Available
Metabolic Pathways Not Available
Biofluid Location Not Available
Tissue Location

  • Epidermis

Normal Biofluid Concentrations Not Available
Normal Tissue Concentrations Not Available
Diseases / Conditions Related to Nutrition Not Available
Other (Monogenic Disorders) Not Available
Abnormal Biofluid Concentrations Not Available
Abnormal Tissue Concentrations Not Available
Physiological Processes Not Available
Authors:
Affiliations:

Contents

Introduction

guidelines
11,12-Epoxyeicosatrienoic acid is an epoxyeicosatrienoic acid (EET). Induction of CYP2C8 in native coronary artery endothelial cells by beta-naphthoflavone enhances the formation of 11,12-epoxyeicosatrienoic acid, as well as endothelium-derived hyperpolarizing factor-mediated hyperpolarization and relaxation. Transfection of coronary arteries with CYP2C8 antisense oligonucleotides resulted in decreased levels of CYP2C and attenuated the endothelium-derived hyperpolarizing factor-mediated vascular responses. Thus, a CYP-epoxygenase product is an essential component of the endothelium-derived hyperpolarizing factor-mediated relaxation in the porcine coronary artery, and CYP2C8 fulfills the criteria for the coronary endothelium-derived hyperpolarization factor synthase. The role of EETs in regulation of the cerebral circulation has become more important, since it was realized that EETs are produced in another specialized cell type of the brain, the astrocytes. It has become evident that EETs released from astrocytes may mediate cerebral functional hyperemia. Molecular and pharmacological evidence hve shown that neurotransmitter release and spillover onto astrocytes can generate EETs. Since these EETs may reach the vasculature via astrocyte foot-processes, they have the same potential as their endothelial counterparts to hyperpolarize and dilate cerebral vessels. P450 enzymes contain heme in their catalytic domain and nitric oxide (NO) appears to bind to these heme moieties and block formation of P450 products, including EETs. Thus, there appears to be crosstalk between P450 enzymes and NO/NO synthase. The role of fatty acid metabolites and cerebral blood flow becomes even more complex in light of data demonstrating that cyclooxygenase products can act as substrates for P450 enzymes. (PMID: 17494091, 17468203, 17434916, 17406062, 17361113, 15581597, 11413051, 10519554)

Biological Function

guidelines

Catabolism

guidelines

Diseases / Conditions Related to Nutrition

guidelines


Other (Monogenic) Disorders

guidelines


Nutritional Information

guidelines

Drivers for biological variation

guidelines

Vulnerable groups

guidelines

Other resources

guidelines

Links

guidelines